Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Sagnelli, N. Coppola, C. Scolastico, A. Mogavero, P. Filippini, F. Piccinino (2001)
CV genotype and “silent” HBV coinfection: Two main risk factors for a more severe liver diseaseJournal of Medical Virology, 64
R. Fukuda, N. Ishimura, M. Niigaki, S. Hamamoto, S. Satoh, Shino Tanaka, Y. Kushiyama, Y. Uchida, S. Ihihara, S. Akagi, M. Watanabe, Y. Kinoshita (1999)
Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus‐associated chronic liver disease: Clinical and virological significanceJournal of Medical Virology, 58
A. Zignego, R. Fontana, S. Puliti, S. Barbagli, M. Monti, G. Careccia, F. Giannelli, C. Giannini, G. Buzzelli, M. Brunetto, F. Bonino, P. Gentilini (1997)
Relevance of inapparent coinfection by hepatitis B virus in alpha interferon‐treated patients with hepatitis C virus chronic hepatitisJournal of Medical Virology, 51
O. Reichard, R. Schvarcz, O. Weiland (1997)
Therapy of hepatitis C: Alpha interferon and ribavirinHepatology, 26
K. Koike, Y. Nakamura, M. Kobayashi, S. Takada, T. Urashima, K. Saigo, S. Kobayashi, K. Isono, I. Hayashi, A. Fujii (1996)
Hepatitis B virus DNA integration frequently observed in the hepatocellular carcinoma DNA of hepatitis C virus-infected patients.International journal of oncology, 8 4
K. Morita, Katsuaki Tanaka, S. Saito, T. Kitamura, M. Kondo, T. Sakaguchi, M. Morimoto, T. Kiba, K. Numata, H. Okazaki, H. Sekihara (1998)
Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C.Journal of medical virology, 58 4
K. Lindsay, G. Davis, E. Schiff, H. Bodenheimer, Balart La, J. Dienstag, R. Perrillo, C. Tamburro, J. Goff, G. Everson, Marcelo Silva, W. Katkov, Z. Goodman, J. Lau, G. Maertens, J. Gogate, B. Sanghvi, J. Albrecht (1996)
Response to higher doses of interferon alfa‐2b in patients with chronic hepatitis C: A randomized multicenter trialHepatology, 24
M. Ziol, J. Nhieu, F. Roudot-thoraval, Métreau Jm, Y. Deugnier, D. Dhumeaux, E. Zafrani (1996)
A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C.Journal of hepatology, 25 6
P. Marcellin, Jean-Pierre Benhamou (1994)
Treatment of chronic viral hepatitis.Bailliere's clinical gastroenterology, 8 2
L. Pagliaro, A. Craxì, C. Cammaá, F. Tiné, V. Marco, O. Iacono, P. Almasio (1994)
Interferon‐α for chronic hepatitis C: An analysis of pretreatment clinical predictors of responseHepatology, 19
(1997)
Management of hepatitis C, March 24±26, 1997
J. McHutchison, S. Gordon, E. Schiff, M. Shiffman, William Lee, V. Rustgi, Z. Goodman, M. Ling, S. Cort, J. Albrecht (1998)
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.The New England journal of medicine, 339 21
T Poynard, P Bedossa, M Chevalier, P Mathurin, C Lemonnier, C Trépo, P Couzigou, JL Payen, M Sajus, JM Costa (1995)
A comparison of three interferon alpha‐2b regimens for long term treatment of chronic non‐A, non‐B hepatitis, 332
M. Callery, T. Kamei, M. Flye (1990)
The anatomic site-specificity of tolerance induction to alloantigen.Transplantation, 49 1
R. Lin, E. Roach, M. Zimmerman, S. Strasser, G. Farrell (1995)
Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates: Results of the first multicentre Australian trialJournal of Hepatology, 23
R. Fukuda, N. Ishimura, Y. Kushiyama, N. Moriyama, S. Ishihara, S. Nagasawa, T. Miyake, M. Niigaki, S. Satoh, S. Sakai, S. Akagi, M. Watanabe, S. Fukumoto (1997)
Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver.Journal of hepatology, 26 3
P. Simmonds, A. Alberti, H. Alter, F. Bonino, D. Bradley, C. Bréchot, J. Brouwer, Shiu-Wan Chan, K. Chayama, Ding‐Shinn Chen, Q. Choo, M. Colombo, H. Cuypers, T. Date, G. Dusheiko, J. Esteban, O. Fay, S. Hadziyannis, Jang Han, A. Hatzakis, E. Holmes, H. Hotta, M. Houghton, B. Irvine, M. Kohara, J. Kolberg, G. Kuo, J. Lau, P. Lelie, G. Maertens, F. Mcomish, T. Miyamura, M. Mizokami, A. Nomoto, A. Prince, H. Reesink, C. Rice, M. Roggendorf, S. Schalm, T. Shikata, K. Shimotohno, L. Stuyver, C. Trepo, A. Weiner, P. Yap, M. Urdea (1994)
A proposed system for the nomenclature of hepatitis C viral genotypesHepatology, 19
M. Sardo, G. Rodinò, S. Brancatelli, M. Pernice, S. Campo, G. Squadrito, F. Russo, G. Raimondo (2008)
Inapparent "wild-type" and "e-minus variant" HBV infection in patients with HCV-related chronic hepatitis.Liver, 14 5
A. Mason, Lizhe Xu, Linsheng Guo, M. Kuhns, R. Perrillo (1998)
Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigenHepatology, 27
T. Poynard, V. Ratziu, Y. Benmanov, V. Martino, P. Bedossa, P. Opolon (2000)
Fibrosis in Patients with Chronic Hepatitis C: Detection and SignificanceSEMINARS IN LIVER DISEASE, Volume 20
D. Powell, B. Abramson, J. Balint, S. Belle, J. Bloomer, A. Diehl, J. Frakes, G. Garcia-Tsao, E. Hook, J. Lusher, M. Popovsky, L. Rabeneck, A. Williams, T. Tralka, H. Alter, M. Alter, E. Bray, L. Curtis, J. Everhart, S. Feinstone, J. Ferguson, J. Gress, W. Hall, J. Hoofnagle, Leslye Johnson, T. Kresina, K. Lindsay, A. Lok, P. McCurdy, R. Perrillo, R. Purcell, E. Schiff, W. Schwieterman, L. Seeff, C. Sherman, M. Stolar, A. Trachtenberg (1997)
National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis CHepatology, 26
JG McHutchison, SC Gordon, ER Schiff, ML Shiffman, WM Lee, VK Rustgi, ZD Goodman, MH Ling, S Cort, JK Albrecht (1998)
Interferon alfa‐2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C, 339
O. Chazouillères, D. Mamish, Michael Kim, K. Carey, TeresaL Wright, L. Ferrell, J. Roberts, N. Ascher (1994)
"Occult" hepatitis B virus as source of infection in liver transplant recipientsThe Lancet, 343
L. Chemello, P. Bonetti, L. Cavalletto, F. Talato, V. Donadon, P. Casarin, F. Belussi, M. Frezza, F. Noventa, P. Pontisso, L. Benvegnu', C. Casarin, A. Alberti (1995)
Randomized trial comparing three different regimens of alpha‐2a‐interferon in chronic hepatitis CHepatology, 22
T. Poynard, V. Leroy, M. Cohard, T. Thévenot, P. Mathurin, P. Opolon, J. Zarski (1996)
Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and durationHepatology, 24
R. Testa, E. Giannini, A. Picciotto, D. Risso, S. Caglieris, A. Fasoli, P. Lantieri, G. Icardi, G. Lapertosa, G. Celle (1999)
Probability of non-response during interferon therapy in patients with chronic hepatitis C.Hepato-gastroenterology, 46 27
M Martinot‐Peignoux, P Marcellin, M Pouteau, C Castelnau, N Boyer, M Poliquin, C Degott, I Descombes, V Le Breton, V Milotova (1995)
Pretreatment serum HCV‐RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C, 22
L. Pagliaro, A. Craxì, C. Cammaá, F. Tiné, V. Marco, O. Iacono, P. Almasio (1994)
Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response.Hepatology, 19 4
B. Roche, Didier Samuel, M. Gigou, C. Féray, V. Virot, Laurent Schmets, M. David, J. Arulnaden, A. Bismuth, Michel Reynes, H. Bismuth (1997)
De novo and apparent de novo hepatitis B virus infection after liver transplantation.Journal of hepatology, 26 3
M. Martinot-Peignoux, P. Marcellin, M. Pouteau, C. Castelnau, N. Boyer, M. Poliquin, C. Degott, Isabelle Descombes, V. Breton, Véronica Milotova, J. Benhamou, S. Erlinger (1995)
Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis CHepatology, 22
T. Urashima, K. Saigo, Susumu Kobayashi, H. Imaseki, H. Matsubara, Y. Koide, Takehide Asano, Y. Kondō, K. Koike, K. Isono (1997)
Identification of hepatitis B virus integration in hepatitis C virus-infected hepatocellular carcinoma tissues.Journal of hepatology, 26 4
T Poynard, V Ratziu, Y Benmanov, V Di Martino, P Bedossa, P Opolon (2000)
Fibrosis in patients with hepatitis C: detection and significance, 20
H. Marusawa, S. Uemoto, M. Hijikata, Y. Ueda, Koichi Tanaka, K. Shimotohno, T. Chiba (2000)
Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigenHepatology, 31
Lawrence Serfaty, Philippe Giral, Alain Loria, T. Andréani, Claire Legendre, Raoul Poupon (1994)
Factors predictive of the response to interferon in patients with chronic hepatitis C.Journal of hepatology, 21 1
T. Poynard, P. Bedossa, M. Chevallier, P. Mathurin, C. Lemonnier, C. Trépo, P. Couzigou, J. Payen, M. Sajus, J. Costa (1995)
A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group.The New England journal of medicine, 332 22
Liaw Yf, Rong-Nan Chien, Shi-Ming Lin, Chau-Ting Yeh, Tsai Sl, Sheen Is, Chu Cm (1997)
Response of patients with dual hepatitis B virus and C virus infection to interferon therapy.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 17 8
M. Prieto, M. Gómez, M. Berenguer, J. Córdoba, J. Rayón, M. Pastor, A. García-Herola, D. Nicolás, D. Carrasco, J. Orbis, J. Mir, J. Berenguer (2001)
De novo hepatitis B after liver transplantation from hepatitis B core antibody—Positive donors in an area with high prevalence of anti‐HBc positivity in the donor populationLiver Transplantation, 7
(1998)
Hepatitis Interventional Therapy group (IHIT)
V. Desmet, M. Gerber, J. Hoofnagle, M. Manns, P. Scheuer (1994)
Classification of chronic hepatitis: Diagnosis, grading and stagingHepatology, 19
H. Yatsuhashi, T. Fujino, T. Matsumoto, O. Inoue, M. Koga, M. Yano (1999)
Immunohistochemical analysis of hepatic interferon alpha-beta receptor level: relationship between receptor expression and response to interferon therapy in patients with chronic hepatitis C.Journal of hepatology, 30 6
A. Bisceglie, Paul Martin, C. Kassianides, M. Lisker‐Melman, Linda Murray, J. Waggoner, Z. Goodman, S. Banks, J. Hoofnagle (1989)
Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.The New England journal of medicine, 321 22
(1999)
Aspetti virologici e clinici delle infezioni multiple da virus epatitici: dati preliminari di uno studio multicentrico nazionale
O Reichard, G Norkrans, A Fryden, JH Braconier, A Sonnerborg, O Weiland (1998)
Randomised, double‐blind, placebo‐controlled trial of interferon a‐2b with and without ribavirin for chronic hepatitis C, 351
M. Wachs, W. Amend, N. Ascher, P. Bretan, J. Emond, J. Lake, J. Melzer, J. Roberts, S. Tomlanovich, F. Vincenti, P. Stock (1995)
The Risk Of Transmission Of Hepatitis B From Hbsag(-), Hbcab(+), Hbigm(-) Organ DonorsTransplantation, 59
O. Reichard, G. Norkrans, A. Frydén, J. Braconier, A. Sönnerborg, O. Weiland (1998)
Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis CThe Lancet, 351
GL Davis, LA Balart, ER Schiff, K Lindsay, HC Bodenheimer, RP Perrillo, W Carey, IM Jacobson, J Payne, JL Dienstag (1989)
Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomized, controlled trial, 321
J. Lowell, T. Howard, S. Shenoy, H. White, D. Brennan, M. Peters, P. Huettner (1995)
Serological evidence of past hepatitis B infection in liver donor and hepatitis B infection in liver allograftThe Lancet, 345
E. Mizukoshi, S. Kaneko, M. Yanagi, H. Ohno, K. Kaji, S. Terasaki, A. Shimoda, E. Matsushita, Kenichi Kobayashi (1998)
Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patientsJournal of Medical Virology, 56
M. Weltman, Brotodihardjo Ae, E. Crewe, G. Farrell, M. Bililus, J. Grierson, Christopher Liddle (1995)
Coinfection with hepatitis B and C or B, C and δ viruses results in severe chronic liver disease and responds poorly to terferon‐a treatmentJournal of Viral Hepatitis, 2
A. Bisceglie, H. Conjeevaram, M. Fried, R. Sallie, Y. Park, C. Yurdaydın, M. Swain, D. Kleiner, K. Mahaney, J. Hoofnagle (1995)
Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.Annals of internal medicine, 123 12
E. Sagnelli, N. Coppola, C. Scolastico, P. Filippini, T. Santantonio, T. Stroffolini, F. Piccinino (2000)
Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitisHepatology, 32
Edoardo Cervoni (1998)
Hepatitis CThe Lancet, 351
G. Davis, Balart La, E. Schiff, K. Lindsay, H. Bodenheimer, R. Perrillo, W. Carey, I. Jacobson, J. Payne, J. Dienstag, D. Vanthiel, C. Tamburro, J. Lefkowitch, J. Albrecht, C. Meschievitz, T. Ortego, A. Gibas (1989)
Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaThe New England Journal of Medicine, 321
(1995)
for The TriVeneto Viral Hepatitis group.
(1980)
AmantadineReactions, 5
N. Zein, J. Rakela, E. Krawitt, K. Reddy, T. Tominaga, D. Persing (1996)
Hepatitis C Virus Genotypes in the United States: Epidemiology, Pathogenicity, and Response to Interferon TherapyAnnals of Internal Medicine, 125
K. Koike, Midori Kobayashi, Morio Gondo, Izumi Hayashi, T. Osuga, S. Takada (1998)
Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus‐infected chronic hepatitis patientsJournal of Medical Virology, 54
I. Cacciola, T. Pollicino, G. Squadrito, G. Cerenzia, M. Orlando, G. Raimondo (1999)
Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.The New England journal of medicine, 341 1
M. Martinot‐Peignoux, N. Boyer, M. Pouteau, C. Castelnau, N. Giuily, V. Duchatelle, A. Aupérin, C. Degott, J. Benhamou, S. Erlinger, P. Marcellin (1999)
Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.Journal of hepatology, 29 2
T. Poynard, P. Marcellin, Samuel Lee, C. Niederau, International Group (1998)
Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusThe Lancet, 352
F. Tiné, S. Magrin, A. Craxì, L. Pagliaro (1991)
Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials.Journal of hepatology, 13 2
‘‘Isolated’’ Anti-HBc and Interferon Therapy
The sustained response to interferon‐α treatment was evaluated in 147 anti‐HCV/HCV‐RNA‐positive, HBsAg‐negative, chronic hepatitis patients, according to HCV genotypes and the presence or absence of anti‐HBs and anti‐HBc. These patients had been included in a controlled study on the safety, tolerability, and efficacy of three types of interferon‐α given at a dose of 3 MU three times weekly for 52 weeks. One hundred and two patients had HCV genotype 1, 42 a non‐1 HCV genotype and 3 multiple HCV genotypes; 46 were anti‐HBs and anti‐HBc negative (group A), 50 anti‐HBs and anti‐HBc positive (group B), and 51 anti‐HBs negative and anti‐HBc positive (“isolated” anti‐HBc, group C). Serum HBV‐DNA was detected by polymerase chain reaction in 15 of the 51 (29.4%) patients in group C and in none of those in groups A or B. The Sustained Response rate was higher in patients with a non‐1 HCV genotype than those with HCV genotype 1 (31% vs. 17.7%, P > 0.1). Fewer patients in group C showed a sustained response than in group A or group B (7.8% vs. 30.4%, P = 0.009 and 7.8% vs 28%, P = 0.017, respectively). Moreover, the sustained response rate was high in patients with a non‐1 genotype, both in group A (42.8%) and in group B (42.8%), intermediate in patients with HCV genotype 1 (23.3% in group A and 22.2% in group B) and low in group C, irrespective of HCV genotype (8.3% for genotype 1 and 7.1% for other genotypes). The data indicate that patients with HCV chronic hepatitis and isolated anti‐HBc show a poor response to IFN‐α, irrespective of the HCV genotype. J. Med. Virol. 65:681–687, 2001. © 2001 Wiley‐Liss, Inc.
Journal of Medical Virology – Wiley
Published: Jan 1, 2001
Keywords: ; ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.